Semaglutide 500mcg

Description

Semaglutide 500mcg is the starting dose of the most transformative GLP-1 receptor agonist in modern pharmacology — the compound that has fundamentally changed the conversation around obesity, metabolic health, and body composition management. At 500mcg weekly, this is the initiation dose: enough to establish receptor engagement and begin the appetite-suppressing, gastric-emptying-slowing, insulin-sensitising effects, while minimising the gastrointestinal side effects (nausea, vomiting, satiety) that characterise higher doses in unaccustomed users. Semaglutide works by mimicking endogenous GLP-1 action — activating hypothalamic appetite circuits to reduce food intake, stimulating insulin secretion in a glucose-dependent manner, and driving improvements in blood glucose, HbA1c, and cardiovascular risk markers. Clinical trial data from SURMOUNT and SELECT trials demonstrate average body weight reductions of 15–20% over 68 weeks at therapeutic doses, with significant cardiovascular event reduction as a secondary benefit. Start here. Titrate with discipline. Verified at 99%+ purity by Puralytix. Inject subcutaneously once weekly — the abdomen, thigh, or upper arm are all suitable sites. Rotate injection sites to prevent local lipodystrophy. At 500mcg weekly, food intake reduction is mild at initiation — the compound is establishing receptor engagement. GI side effects (nausea, mild bloating) are typically transient and diminish within 2–4 weeks as the body adapts to sustained GLP-1 receptor activation.